HPLC-MS Analysis of Four Potential Genotoxic Impurities in Alogliptin Pharmaceutical Materials.

This study focuses on hplc-ms analysis of four potential genotoxic impurities in alogliptin pharmaceutical materials.. The research employs high-performance liquid chromatography (HPLC) techniques to address analytical challenges in the pharmaceutical field. Pyridine, 3-aminopyridine, 4-dimethylaminopyridine, and N, N-dimethylamine are reactive bases that may be used in the preparation of the pharmaceutical ingredient alogliptin (ALO). They are considered as potentially genotoxic impurities (PGIs) since they contain electrophilic functional groups. Therefore, they should be monitored at the allowed limits in ALO.... Research Background and Significance The pharmaceutical industry demands rigorous analytical techniques to ensure the safety and quality of active pharmaceutical ingredients (APIs). Alogliptin (ALO), a dipeptidyl peptidase-4 inhibitor used in the management of type 2 diabetes, is synthesized via chemical routes that may introduce trace levels of potential genotoxic impurities (PGIs). PGIs such as pyridine, 3-aminopyridine, 4-dimethylaminopyridine, and N,N-dimethylamine are of particular concern due to their electrophilic functional groups, which can pose mutagenic risks if present above regulatory thresholds. Monitoring these impurities at trace levels is critical for compliance with regulatory guidelines and patient safety. The study by Al-Sabti and Harbali (2022) addresses this challenge through the development and validation of a high-performance liquid chromatography coupled with mass spectrometry (HPLC-MS) method capable of sensitive and selective quantification of these PGIs in ALO drug substances. This research holds high significance as it supports pharmaceutical quality control and risk management by providing a robust analytical tool for detecting